NCT00865033已完成1 期
A Relative Bioavailability Study of Metformin HCL 1000 mg Tablets Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 32
- 主要终点
- Bioequivalence according to US FDA guidelines
研究概览
简要总结
The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Metformin HCL Tablets, 1000 mg
干预措施: Metformin HCL Tablets, 1000 mg Sandoz (Drug)
2
Active Comparator
Glucophage 1000 mg Tablets
干预措施: Glucophage 1000 mg (Drug)
结局指标
主要结局
Bioequivalence according to US FDA guidelines
时间窗: 9 days
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting ConditionsHealthyNCT00778141Ranbaxy Laboratories Limited36
撤回
1 期
Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated TabletComparative BioavailabilityNCT02217670Disphar International B.V.
已完成
1 期
To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting ConditionsType II DiabetesNCT00882882Sandoz16
已完成
1 期
A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting ConditionsHealthyNCT00865839Actavis Inc.32
已完成
1 期
A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting ConditionsHealthyNCT00864669Actavis Inc.32